ARCALIS
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese CDMO providing integrated mRNA/LNP development and manufacturing services, with a focus on oncology and vaccine applications.
Oncology
Technology Platform
Integrated mRNA and lipid nanoparticle (LNP) platform offering design, optimization, and manufacturing services, including expertise in self-amplifying mRNA (saRNA) technology.
Opportunities
Growing demand for mRNA CDMO services in Asia and for next-generation saRNA platforms; expansion into drug product manufacturing by 2026 creates a full one-stop-shop offering.
Risk Factors
High capital expenditure for facility build-out without guaranteed client demand; intense competition in the mRNA CDMO space from larger, established global players.
Competitive Landscape
Competes with global mRNA CDMOs like Lonza, Catalent, and regional Asian manufacturers; differentiates through speed (3-month development timelines), integrated services, and saRNA expertise.